MMM

3M Company (MMM) - Q2 2006 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2006. 3M is a diversified global manufacturer operating in six segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Electro and Communications, and Safety, Security and Protection Services. Effective Q1 2006, the company realigned its segments (combining Industrial and Transportation) and adopted SFAS No. 123R, requiring the expensing of stock-based compensation using a modified retrospective method.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7.5% in Q2 2006, driven by 4.8% organic volume growth and 2.6% from acquisitions (primarily CUNO). Local-currency sales grew 7.2%.
• Profitability: While Net Income and EPS increased significantly (17% and 19.8% respectively), Operating Income declined 5.5% year-over-year. This decline was primarily due to higher stock-based compensation expense ($54 million increase in Q2) and special items.
• Tax Rate: The effective tax rate dropped to 23.3% from 38.2% in the prior year, largely due to a $105 million reduction in tax reserves following audit settlements.
• Cash Flow: Operating cash flow decreased $707 million year-over-year (YTD) due to higher tax payments ($1 billion vs. $500 million prior year) and increased inventory build-up.
• Segment Performance:
  • Industrial & Transportation: Sales up 11.4%; Operating income up 2.8%.
  • Health Care: Sales up 4.4%; Operating income down 8.2% due to stock option expensing and costs related to exploring strategic alternatives for its pharmaceutical business.
  • Display & Graphics: Sales up 6.9%; Operating income down 13.0% due to softer optical film volumes, unfavorable LCD mix, and operational challenges at a new facility.

Guidance, Outlook, and Risks

• Strategic Alternatives: 3M is actively pursuing strategic alternatives for its branded pharmaceuticals business (approx. 20% of Health Care sales). Initial bids have been received, and due diligence is ongoing. Restructuring charges are expected to continue.
• Capital Allocation: The Board authorized a $2 billion stock repurchase program (Feb 2006–Feb 2007) and increased the quarterly dividend by 9.5% to $0.46 per share (48th consecutive year of increases).
• Outlook: Management expects LCD industry fundamentals to improve in the second half of the year. Capital expenditures are projected to be approximately $1.1 billion for the full year 2006.
• Legal & Regulatory Risks:
  • Antitrust: Reached an agreement in principle to settle a direct purchaser transparent tape antitrust class action for approximately $40 million (pending court approval).
  • Asbestos/Respirator: Named defendant in ~33,000 lawsuits; liability is not reliably estimable beyond current reserves.
  • Environmental (PFOA/PFOS): Ongoing regulatory reviews in the US, Canada, and EU regarding perfluorooctanyl compounds. The company is funding water treatment systems in Minnesota and monitoring environmental impact.

Investor Verification Checklist

• Stock-Based Compensation Impact: Verify the sustainability of earnings given the $54 million Q2 increase in stock option expense due to the new SFAS 123R vesting rules for retirement-eligible employees.
• Pharmaceutical Divestiture: Monitor progress on the sale of the branded pharmaceuticals business and associated restructuring costs.
• Display & Graphics Margins: Assess the timeline for recovery in optical film margins amidst LCD industry inventory corrections and pricing pressure.
• Tax Reserve Volatility: Note the $105 million tax reserve reduction; verify if future tax provisions will normalize to historical rates.
• Antitrust Settlement: Confirm final court approval of the $40 million transparent tape settlement.